Randomized trial of tracolimus versus cyclosporin microemulsion in renal transplantation

Richard Trompeter, Guido Filler, Nicholas J.A. Webb, Alan R. Watson, David V. Milford, Gunnar Tyden, Ryszard Grenda, Jan Janda, David Hughes, Jochen H.H. Ehrich, Bernd Klare, Graziella Zacchello, Inge Bjorn Brekke, Mary McGraw, Ferenc Perner, Lucian Ghio, Egon Balzar, Styrbjörn Friman, Rosanna Gusmano, Jochen Stolpe

Research output: Article

181 Citations (Scopus)

Abstract

This study was undertaken to compare the efficacy and safety of tacrolimus (Tac) with the microemulsion formulation of cyclosporin (CyA) in children undergoing renal transplantation. A 6-month, randomized, prospective, open, parallel group study with an open extension phase was conducted in 18 centers from nine European countries. In total, 196 pediatric patients (<18 years) were randomly assigned (1:1) to receive either Tac (n=103) or CyA microemulsion (n=93) administered concomitantly with azathioprine and corticosteroids. The primary endpoint was incidence and time to first acute rejection. Baseline characteristics were comparable between treatment groups. Tac therapy resulted in a significantly lower incidence of acute rejection (36.9%) compared with CyA therapy (59.1%) (P=0.003). The incidence of corticosteroid-resistant rejection was also significantly lower in the Tac group compared with the CyA group (7.8% vs. 25.8%, P=0.001). The differences were also significant for biopsy-confirmed acute rejection (16.5% vs. 39.8%, P<0.001). At 1 year, patient survival was similar (96.1% vs. 96.6%), while 10 grafts were lost in the Tac group compared with 17 graft losses in the CyA group (P=0.06). At 1 year, mean glomerular filtration rate (Schwartz estimate) was significantly higher in the Tac group (62±20 ml/min per 1.73 m2, n=84) than in the CyA group (56±21 ml/min per 1.73 m2, n=74, P=0.03). The most frequent adverse events during the first 6 months were hypertension (68.9% vs. 61.3%), hypomagnesemia (34.0% vs. 12.9%, P=0.001), and urinary tract infection (29.1% vs. 33.3%). Statistically significant differences (P<0.05) were observed for diarrhea (13.6% vs. 3.2%), hypertrichosis (0.0% vs. 7.5%), flu syndrome (0.0% vs. 5.4%), and gum hyperplasia (0.0% vs. 5.4%). In previously non-diabetic children, the incidence of long-term (>30 days) insulin use was 3.0% (Tac) and 2.2% (CyA). Post-transplant lymphoproliferative disease was observed in 1 patient in the Tac group and 2 patients in the CyA group. In conclusion, Tac was significantly more effective than CyA microemulsion in preventing acute rejection after renal transplantation in a pediatric population. The overall safety profiles of the two regimens were comparable.

Original languageEnglish
Pages (from-to)141-149
Number of pages9
JournalPediatric Nephrology
Volume17
Issue number3
DOIs
Publication statusPublished - dec. 1 2002

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Fingerprint Dive into the research topics of 'Randomized trial of tracolimus versus cyclosporin microemulsion in renal transplantation'. Together they form a unique fingerprint.

  • Cite this

    Trompeter, R., Filler, G., Webb, N. J. A., Watson, A. R., Milford, D. V., Tyden, G., Grenda, R., Janda, J., Hughes, D., Ehrich, J. H. H., Klare, B., Zacchello, G., Brekke, I. B., McGraw, M., Perner, F., Ghio, L., Balzar, E., Friman, S., Gusmano, R., & Stolpe, J. (2002). Randomized trial of tracolimus versus cyclosporin microemulsion in renal transplantation. Pediatric Nephrology, 17(3), 141-149. https://doi.org/10.1007/s00467-001-0795-9